Table 1.
Real-world treatment pattern and baseline characteristics of Endostar plus different chemotherapy in all patients.
| Variables | All patients | Endostar plus NP | Endostar plus DP | Endostar plus GP | Endostar plus PP | Endostar plus TP |
|---|---|---|---|---|---|---|
| N (%) | 512 | 53 (10.35) | 79 (15.43) | 166 (32.42) | 136 (26.56) | 78 (15.23) |
| Age, years | ||||||
| Mean ± SD | 58.1 ± 10.0 | 57.0 ± 8.2 | 57.9 ± 9.6 | 59.2 ± 9.3 | 56.4 ± 11.7 | 59.3 ± 9.3 |
| Median (Q1-Q3) | 59.2 (51.3–65.0) | 56.1 (51.0–62.0) | 58.1 (50.3–65.6) | 60.1 (53.5–65.7) | 58.6 (48.0–65.0) | 59.6 (54.1–65.4) |
| Sex, n (%) | ||||||
| Unknown | 14 (2.7) | 2 (3.8) | 2 (2.5) | 5 (3.0) | 1 (0.7) | 4 (5.1) |
| Male | 385 (75.2) | 35 (66.0) | 55 (69.6) | 146 (88.0) | 86 (63.2) | 63 (80.8) |
| Female | 113 (22.1) | 16 (30.2) | 22 (27.8) | 15 (9.0) | 49 (36.0) | 11 (14.1) |
| Smoking history | ||||||
| No | 185 (36.1) | 24 (45.3) | 31 (39.2) | 44 (26.5) | 70 (51.5) | 16 (20.5) |
| Yes | 327 (63.9) | 29 (54.7) | 48 (60.8) | 122 (73.5) | 66 (48.5) | 62 (79.5) |
| Family history of lung cancer | ||||||
| No | 493 (96.3) | 51 (96.2) | 77 (97.5) | 163 (98.2) | 131 (96.3) | 71 (91.0) |
| Yes | 19 (3.7) | 2 (3.8) | 2 (2.5) | 3 (1.8) | 5 (3.7) | 7 (9.0) |
| Disease stage | ||||||
| III | 188 (36.7) | 21 (39.6) | 33 (41.8) | 83 (50.0) | 21 (15.4) | 30 (38.5) |
| IV | 324 (63.3) | 32 (60.4) | 46 (58.2) | 83 (50.0) | 115 (84.6) | 48 (61.5) |
| Pathological type | ||||||
| Squamous cell carcinoma | 181 (35.4) | 20 (37.7) | 36 (45.6) | 99 (59.6) | 6 (4.4) | 20 (25.6) |
| Adenocarcinoma | 205 (40.0) | 19 (35.8) | 37 (46.8) | 8 (4.8) | 116 (85.3) | 25 (32.1) |
| Unknown | 118 (23.0) | 12 (22.6) | 3 (3.8) | 59 (35.5) | 12 (8.8) | 32 (41.0) |
| Other | 8 (1.6) | 2 (3.8) | 3 (3.8) | 0 (0) | 2 (1.5) | 1 (1.3) |
| Patient type | ||||||
| Treatment-naïve | 417 (81.4) | 26 (49.1) | 54 (68.4) | 148 (89.2) | 122 (89.7) | 67 (85.9) |
| Re-treatment | 95 (18.6) | 27 (50.9) | 25 (31.6) | 18 (10.8) | 14 (10.3) | 11 (14.1) |